金币
UID775752
帖子
主题
积分4653
注册时间2022-1-12
最后登录1970-1-1
听众
性别保密
|
发表于 2022-5-18 10:05:51
|
显示全部楼层
我在WHO TRS1010 ANNEX 10(2018年发布)关于稳定性研究的指南里,也是只看到了关于长期稳定性的检测时间要求如下——2.2.6 Testing frequency
For long-term studies, frequency of testing should be sufficient to establish the stability profile of the FPP.
For products with a proposed shelf life of at least 12 months, the frequency of testing at the long-term storage condition should normally be every three months over the first year, every six months over the second year and annually thereafter throughout the proposed shelf life.
参考中译——
2.2.6 测试频率
对于长期研究,测试的频率应足以建立FPP的稳定性概况。
对于建议货架有效期至少为12个月的产品,在长期储存条件下的测试频率通常应为第一年每三个月一次,第二年每六个月一次,此后在建议货架有效期内每年一次。
所谓有效期后一年,通常也是对留样样品的存储要求,例如WHO TRS986 ANNEX2的GMP主原则中,写到:“17.21 Retention samples from each batch of finished product should be kept for at least one year after the expiry date. Finished products should usually be kept in their final packaging and stored under the recommended conditions. If exceptionally large packages are produced, smaller samples might be stored in appropriate containers. Samples of active starting materials should be retained for at least one year beyond the expiry date of the corresponding finished product. Other starting materials (other than solvents, gases and water) should be retained for a minimum of two years if their stability allows. Retention samples of materials and products should be of a size sufficient to permit at least two full reexaminations.”
翻译过来,前两句的内容就与中国GMP(2010版)的第十章 质量保证与质量控制中第二百二十五条,要求(三) 成品的留样的第2、6条描述基本一致:
2.留样的包装形式应当与药品市售包装形式相同,原料药的留样如无法采用市售包装形式的,可采用模拟包装;
......
6.留样应当按照注册批准的贮存条件至少保存至药品有效期后一年;
对物料,在第二百二十五条,要求(四)物料的留样里则有一条补充:
4. 除稳定性较差的原辅料外,用于制剂生产的原辅料(不包括生产过程中使用的溶剂、气体或制药用水)和与药品直接接触的包装材料的留样应当至少保存至产品放行后二年。如果物料的有效
期较短,则留样时间可相应缩短;
|
|